Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Gene Therapy

• Publication date

  2000-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.cgt.7700197PMID 10917201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relative activity and specificity of promoters from prostate‐expressed genes

  1998cited by this paper
• Identification of diphtheria toxin via screening as a potent cell cycle and p53‐independent cytotoxin for human prostate cancer therapeutics

  1998cited by this paper
• Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

  1998cited by this paper
• Specific autologous anti-melanoma T cell response in vitro using monocyte-derived dendritic cells.

  1998cited by this paper
• Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes.

  1998cited by this paper
• Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA–liposome complexes

  1997cited by this paper
• Identification of two novel cis-elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation.

  1997cited by this paper
• Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.

  1997cited by this paper
• Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors.

  1997cited by this paper
• Tyrosinase mRNA is expressed in human substantia nigra.

  1997cited by this paper
• A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans.

  1997cited by this paper
• Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer (*)

  1996cited by this paper
• Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes.

  1996cited by this paper
• In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector

  1996cited by this paper
• Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.

  1996cited by this paper
• Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery.

  1995cited by this paper
• Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression.

  1995cited by this paper
• Prostate Tissue Specificity of the Prostate-Specific Antigen Promoter Isolated from a Patient with Prostate Cancer

  1995cited by this paper
• Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.

  1994cited by this paper
• Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines.

  1994cited by this paper
• Tissue-specific targeting of retroviral vectors through ligand-receptor interactions.

  1994cited by this paper
• Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene.

  1994cited by this paper
• DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis.

  1993cited by this paper
• Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha.

  1992cited by this paper

• Targeted Diphtheria Toxin-Based Therapy: A Review Article

  2019cites this paper
• Review on Gene Therapy of Prostate Cancer

  2018cites this paper
• Increasing cancer-specific gene expression by targeting overexpressed α5β1 integrin and upregulated transcriptional activity of NF-κB.

  2014cites this paper
• SUICIDE GENE THERAPY : COMPARING TWO DIFFERENT APPROACHES IN MELANOMA AND PROSTATE TUMOUR CELLS

  2012cites this paper
• Eukaryotic expression vectors bearing genes encoding cytotoxic proteins for cancer gene therapy.

  2012cites this paper
• Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.

  2009cites this paper
• Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter

  2007cites this paper
• Non‐invasive imaging of firefly luciferase reporter gene expression using bioluminescence imaging in human prostate cancer models

  2007cites this paper
• Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer

  2007cites this paper
• Gene delivery and gene therapy of prostate cancer

  2006cites this paper
• Two‐step transcriptional amplification–lipid‐based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer

  2006cites this paper
• Gene therapy strategies in prostate cancer.

  2005cites this paper
• Novel Experimental Therapeutic Approaches for Prostate Cancer

  2005cites this paper
• Cancer gene therapy

  2005cites this paper
• Endocrine aspects of cancer gene therapy.

  2004cites this paper
• Oncolytic viral therapies

  2004cites this paper
• The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.

  2003cites this paper
• Improving the transcriptional regulation of genes delivered by adenovirus vectors.

  2003cites this paper
• Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A

  2003cites this paper
• Gene regulation in cancer gene therapy strategies.

  2003cites this paper
• Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer.

  2003cites this paper
• Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma

  2003cites this paper
• Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma.

  2002cites this paper
• Cell-specific expression of the diphtheria toxin A-chain coding sequence induces cancer cell suicide.

  2002cites this paper
• Cell-Specific Cre-Mediated Activation of the Diphtheria Toxin Gene in Pituitary Tumor Cells: Potential for Cytotoxic Gene Therapy

  2002cites this paper
• Prostate cancer gene therapy and the role of radiation.

  2002cites this paper
• PG13 Packaging Cells Produce Recombinant Retroviruses Carrying a Diphtheria Toxin Mutant Which Kills Cancer Cells

  2002cites this paper
• The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.

  2001cites this paper
• Prostate-specific targeting using PSA promoter-based lentiviral vectors

  2001cites this paper
• The Use of theL-Plastin Promoter for Adenoviral-mediated , Tumor-specific Gene Expression in Ovarian and Bladder Cancer Cell Lines 1

  2001cites this paper
• Gene therapy for prostate cancer: current status and future prospects.

  2001cites this paper
• Endothelial cell–based systemic gene therapy of metastatic melanoma

  2001cites this paper
• Gene therapy for endocrine tumors: strategies and progress

  2001cites this paper
• Number : DAMD 1799-1-9457 TITLE : Tumor Specific Gene Expression and Tumor Specific Vector Replication for Systemic Chemotherapy Sensitization Treatment of Breast Cancer

  year unknowncites this paper